Environmental & Reproductive Health Risk for Lewy Body Dementia

Status Recruiting

Clinical Trial Summary

The goal of this survey study is to identify environmental, occupational and reproductive health risk factors for Lewy body dementia, which includes Parkinson's disease dementia and dementia with Lewy bodies. Participants will complete a one-time survey online or over the phone that includes questions on environmental, occupational factors they may have been exposed to and on medical history including reproductive health. Researchers will then compare the responses of people with Lewy body dementia and people without Parkinson's or memory/thinking problems to see which factors play a role in Lewy body dementia. Identifying risk factors can guide future treatment efforts and provide more insight to this dementia.

Clinical Trial Description

Lewy body dementia, including Parkinson's disease dementia and dementia with Lewy bodies, is one of the most common dementias and does not have a cure for now. It can occur differently for women and men, although we are not sure why. The ratio of women to men for the disease prevalence changes with older age, suggesting a potential role for reproductive factors, particularly for women. Environmental factors impact the risk for other types of dementia, although such factors have not been clearly described in Lewy body dementia specifically. Women and men may get exposed to different environmental and occupational risk factors, and the impact of factors can differ for women and men. By using one-time survey that can be completed online or over the phone, we will try to understand which environmental, occupational or reproductive health factors play a role in Lewy body dementia for women and men. By comparing the survey responses of people with Lewy body dementia and people without Parkinson's or memory/thinking problems, we aim to identify specific risk factors for women and men that can guide future treatment efforts and provide more insight into this dementia. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06005935
Study type	Observational
Source	University of California, San Diego
Contact	Reilly Thompson
Phone	858-246-3190
Email	r4thompson@health.ucsd.edu
Status	Recruiting
Phase
Start date	August 1, 2023
Completion date	July 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03996460` - K0706 for Patients Diagnosed With Dementia With Lewy Bodies	Phase 2
Recruiting	`NCT04335994` - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing	N/A
Recruiting	`NCT02194816` - Modifiable Variables in Parkinsonism (MVP)
Active, not recruiting	`NCT01208675` - The Swedish BioFINDER Study
Completed	`NCT03538522` - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831	Phase 2
Recruiting	`NCT03672448` - The China Longitudinal Aging Study of Cognitive Impairment
Completed	`NCT01340001` - Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies	N/A
Not yet recruiting	`NCT04760860` - Terazosin for Dementia With Lewy Bodies	Phase 1/Phase 2
Completed	`NCT02910102` - Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia	Phase 2
Terminated	`NCT02928445` - Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension	Phase 2/Phase 3
Terminated	`NCT02871427` - Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder	Phase 2
Completed	`NCT05188105` - Alpha tACS in Dementia With Lewy Bodies	N/A
Active, not recruiting	`NCT04167813` - Trial of Ondansetron as a Parkinson's HAllucinations Treatment	Phase 2
Enrolling by invitation	`NCT04954183` - Development of an EEG Diagnostic for Alzheimer's Disease
Recruiting	`NCT05326750` - Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases	N/A
Completed	`NCT01023672` - "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"	Phase 4
Completed	`NCT03907748` - Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia	N/A
Completed	`NCT04649164` - Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia	N/A
Recruiting	`NCT03924414` - Trial of Parkinson's And Zoledronic Acid	Phase 4
Completed	`NCT05885620` - SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Environmental and Reproductive Health Risk for Lewy Body Dementia — LBD-TOROS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms